Biography and Research Information
OverviewAI-generated summary
Shivangi Shrimali's research investigates new approaches for drug development and toxicity testing, with a focus on microphysiological systems and in vitro methods. She has explored the radioprotective effects of tocotrienols and developed novel analogues for radiomitigation, examining their antioxidant and signaling mechanisms. Her work also includes investigating the impact of substances like titanium dioxide on microRNA expression in human cells. Shrimali's publications address new approach methodologies (NAMs) for evaluating drug-induced liver injury (DILI) and the application of microphysiological systems for assessing drug absorption, distribution, metabolism, excretion, and toxicity. She has collaborated with researchers from the University of Arkansas for Medical Sciences and the University of Arkansas at Fayetteville on multiple shared publications.
Metrics
- h-index: 3
- Publications: 6
- Citations: 20
Selected Publications
-
Exposure to a Titanium Dioxide Product Alters MicroRNA Expression in Human Cells (2026)
-
Microphysiological systems as an emerging in vitro approach for the evaluation of drug absorption, distribution, metabolism, and excretion and toxicity (2025)
-
New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now? (2025)
-
Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects (2023)
-
466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator (2023)
Collaboration Network
Top Collaborators
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now?
- Microphysiological systems as an emerging in vitro approach for the evaluation of drug absorption, distribution, metabolism, and excretion and toxicity
- New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now?
- Microphysiological systems as an emerging in vitro approach for the evaluation of drug absorption, distribution, metabolism, and excretion and toxicity
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects
- New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now?
Similar Researchers
Based on overlapping research topics